Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for biotechnology industry professionals · Tuesday, December 5, 2023 · 673,150,669 Articles · 3+ Million Readers

Biotechnology Contract Manufacturing Market is Expected to Reach $24.8 billion | MarketsandMarkets.

/EIN News/ -- Chicago, Sept. 22, 2023 (GLOBE NEWSWIRE) -- In the near future, the biotechnology contract manufacturing industry is poised to undergo a transformative evolution, fueled by rapid advances in genetic engineering, personalized medicine, and pharmaceutical innovation. This industry, already experiencing substantial growth, is expected to become a pivotal player in the biopharmaceutical landscape. With a surge in demand for custom-designed biologics, vaccines, and gene therapies, contract manufacturers will harness cutting-edge automation, synthetic biology, and data analytics to deliver scalable, cost-effective solutions. Collaboration between biotech firms and contract manufacturers will intensify, leading to streamlined production processes, shorter development timelines, and enhanced flexibility. As a result, the biotechnology contract manufacturing sector is on the cusp of revolutionizing the production of life-saving therapies, making healthcare more accessible, and accelerating the development of groundbreaking treatments for a myriad of diseases.

Biotechnology Contract Manufacturing market in terms of revenue was estimated to be worth $16.6 billion in 2023 and is poised to reach $24.8 billion by 2028, growing at a CAGR of 8.3% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The growth of this market is majorly driven by the rising demand for biologics and biosimilars, the growing focus on personalized medicine, and advancements in manufacturing technologies. Further, the complex structure of biologics makes it more difficult to manufacture, which is likely to increase the outsourced manufacturing, supporting the market growth. Additionally, rising demand for novel therapies like cell therapies and gene therapies and the expansion of biologics manufacturing capacities by CMOs will provide growth opportunities for biotechnology contract manufacturers in the near future.

Download an Illustrative overview:

Biotechnology Contract Manufacturing Market Scope:

Report Coverage Details
Market Revenue in 2023 $16.6 billion
Estimated Value by 2028 $24.8 billion
Growth Rate Poised to grow at a CAGR of 8.3%
Market Size Available for 2021–2028
Forecast Period 2023–2028
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Service, Type, Source, Scale of Operation, Molecule Type, Therapeutic Area, and Region
Geographies Covered North America, Europe, Asia Pacific, Latin America (LATAM), and Middle East and Africa (MEA)
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunities Rising demand for cell therapies and gene therapies
Key Market Drivers Increasing biologics manufacturing outsourcing trend among biopharmaceutical companies

Biotechnology Contract Manufacturing market major players covered in the report, such as:

  • Lonza (Switzerland)
  • Thermo Fisher Scientific Inc. (US)
  • Catalent, Inc. (US)
  • Samsung Biologics (South Korea)
  • WuXi Biologics (China)
  • Boehringer Ingelheim International GmbH (Germany)
  • FUJIFILM Holdings Corporation (Japan)
  • AbbVie, Inc. (US)
  • Eurofins Scientific (Luxembourg)
  • GenScript Biotech Corporation (US)
  • AGC, Inc. (Japan)
  • Merck KGaA (Germany)
  • JSR Corporation (Japan)
  • Stelis (India)
  • Recipharm AB (Sweden)
  • Emergent (US)
  • Shanghai Fosun Pharmaceutical Co., Ltd. (China)
  • LOTTE BIOLOGICS (South Korea)
  • Hepalink Group (China)
  • Curia Global, Inc. (US)
  • JRS Pharma (Germany)
  • MINAPHARM Pharmaceuticals (Egypt)
  • Rentschler Biopharma SE (Germany)
  • Avid Bioservices, Inc. (US)
  • Abzena Ltd. (US)
  • Polyplus Transfection (Germany)
  • Midas Pharma GmbH (Germany)
  • MabPlex International Co., Ltd. (China)
  • Asahi Kasei Corporation (Japan)
  • and Among Others

Buy a Biotechnology Contract Manufacturing Industry Report (336 Pages PDF with Insightful Charts, Tables, and Figures):

This report categorizes the Biotechnology contract manufacturing market into the following segments and subsegments:
Biotechnology contract manufacturing market, by Service

  • Manufacturing
  • Formulation and Fill-Finish
  • Packaging and Labeling
  • Other services

Biotechnology contract manufacturing market, by Type

  • Biologic Drug Substance Manufacturing
  • Biologic Drug Product Manufacturing

Biotechnology contract manufacturing market, by Scale of Operation

  • Commercial Operations
  • Clinical Operations

Biotechnology contract manufacturing market, by Source

  • Mammalian Expression Systems
  • Non-Mammalian Expression Systems

Biotechnology contract manufacturing market, by Molecule

  • Monoclonal Antibodies
  • Cell Therapy & Gene Therapy
  • Antibody-Drug Conjugates (ADCs)
  • Vaccines
  • Therapeutic Peptides & Proteins
  • Other Molecule Types

Biotechnology contract manufacturing market, by Therapeutic Area

  • Oncology
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Neurology
  • Other Therapeutic Areas

Biotechnology contract manufacturing market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
    • Brazil
    • Rest of Latin America
  • Middle East and Africa (MEA)

Request for FREE Sample Pages:

The key stakeholders in the Biotechnology Contract Manufacturing market include:

  • Pharmaceutical and Biotechnology Companies
  • Research and Consulting Firms
  • Academic Medical Centers
  • Government Research Organizations
  • Clinical Research Institutes
  • Contract Research Organizations
  • Pharmaceutical Distributors and Suppliers
  • Corporate Entities
  • Contract Development and Manufacturing Organizations

Recent Developments:

  • In January 2023, WuXi Biologics entered into a licensing agreement with GSK plc for using  WuXi Biologics’ proprietary technology platforms. Under this, GSK was granted an exclusive global license for the research, development, manufacturing, and commercialization of bispecific antibodies in the WuXi Biologics plan.
  • In October 2022, Samsung Biologics partnered with GSK plc for the manufacturing of GSK’s monoclonal antibody and products, including lupus treatments like Benlysta.

Frequently Asked Questions (FAQs) of Biotechnology Contract Manufacturing Market:

Question 1. Who are the key players in the biotechnology contract manufacturing market?
Answer: Key players in the biotechnology contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC, Inc. (Japan), Merck KgaA (Germany), JSR Corporation (Japan), among others.

Question 2: Which service segment dominates the biotechnology contract manufacturing market?
Answer: The manufacturing segment held the largest share of the global biotechnology contract manufacturing market by service segment in 2022. This is primarily attributed to the rising demand for biologics in the biopharmaceutical industry to treat chronic diseases.                

Question 3: Which type of segment dominates the biotechnology contract manufacturing market?
Answer: The biologics drug substance manufacturing segment held the largest market share by type in 2022. Increasing research and development activities for the development of novel drugs are driving the growth of this market.

Question 4: Which source segment of the biotechnology contract manufacturing market is expected to dominate the market?
Answer: The mammalian expression systems segment held the largest share by source in 2022 due to increasing pipelines of mammalian-based biologics and the advantages of mammalian expression systems like proven post-translational modifications, correct protein folding, and improved bioactivity.

Question 5: What is the market size for the biotechnology contract manufacturing market?
Answer: The biotechnology contract manufacturing market is estimated to reach USD 24.8 billion by 2028 from USD 16.6 billion in 2023, at a CAGR of 8.3% during the forecast period of 2023 to 2028.

Get 10% Free Customization on this Report:

Report Objectives:

  • To define, describe, and forecast the biotechnology contract manufacturing market based on service, type, source, scale of operation, molecule type, therapeutic area, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the market

Related Reports:

RNA Therapeutics Market

Biotechnology Contract Manufacturing Market

PDX Model Market

Vascular Access Device Market

RNA Analysis Market

Research Insight:

Content Source:

About MarketsandMarkets™
                    MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
                    MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
                    Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
                    The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
                    Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
                    To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
                    Mr. Aashish Mehra
                    MarketsandMarkets™ INC.
                    630 Dundee Road
                    Suite 430
                    Northbrook, IL 60062
                    USA: +1-888-600-6441

Primary Logo

Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release